These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 31093306)
21. Identification of crucial genes associated with lung adenocarcinoma by bioinformatic analysis. Dai JJ; Zhou WB; Wang B Medicine (Baltimore); 2020 Oct; 99(44):e23052. PubMed ID: 33126397 [TBL] [Abstract][Full Text] [Related]
22. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5. Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092 [TBL] [Abstract][Full Text] [Related]
23. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification]. Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740 [TBL] [Abstract][Full Text] [Related]
24. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311 [TBL] [Abstract][Full Text] [Related]
25. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. Gasparini P; Cascione L; Landi L; Carasi S; Lovat F; Tibaldi C; Alì G; D'Incecco A; Minuti G; Chella A; Fontanini G; Fassan M; Cappuzzo F; Croce CM Proc Natl Acad Sci U S A; 2015 Dec; 112(48):14924-9. PubMed ID: 26627242 [TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224 [TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099 [TBL] [Abstract][Full Text] [Related]
28. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis. Zhou J; Hui X; Mao Y; Fan L Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31311829 [TBL] [Abstract][Full Text] [Related]
29. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells. Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601 [TBL] [Abstract][Full Text] [Related]
30. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL Oncology; 2015; 89(3):175-86. PubMed ID: 25833149 [TBL] [Abstract][Full Text] [Related]
31. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899 [TBL] [Abstract][Full Text] [Related]
32. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis. Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250 [TBL] [Abstract][Full Text] [Related]
33. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636 [TBL] [Abstract][Full Text] [Related]
34. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530 [TBL] [Abstract][Full Text] [Related]
35. [To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung]. Sun PL; Liu JN; Cao LQ; Yao M; Gao HW Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):303-308. PubMed ID: 28468034 [No Abstract] [Full Text] [Related]
36. Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis. Nottegar A; Tabbò F; Luchini C; Guerrera F; Gaudiano M; Bria E; Brunelli M; Chilosi M; Inghirami G Exp Mol Pathol; 2017 Apr; 102(2):276-279. PubMed ID: 28237660 [TBL] [Abstract][Full Text] [Related]
37. Identification of key genes and biological pathways in lung adenocarcinoma via bioinformatics analysis. Wang Y; Zhou Z; Chen L; Li Y; Zhou Z; Chu X Mol Cell Biochem; 2021 Feb; 476(2):931-939. PubMed ID: 33130972 [TBL] [Abstract][Full Text] [Related]
38. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668 [TBL] [Abstract][Full Text] [Related]
39. PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience. Mitiushkina NV; Kholmatov MM; Venina AR; Tiurin VI; Yanus GA; Sokolova TN; Yatsuk OS; Zaitseva OA; Ivantsov AO; Kuligina ES; Togo AV; Imyanitov EN Neoplasma; 2018 Nov; 65(6):972-979. PubMed ID: 30334450 [TBL] [Abstract][Full Text] [Related]
40. Comprehensive Analysis of Candidate Diagnostic and Prognostic Biomarkers Associated with Lung Adenocarcinoma. Li J; Liu X; Cui Z; Han G Med Sci Monit; 2020 Jun; 26():e922070. PubMed ID: 32578582 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]